- Home
- FND vs INAB Comparison
FND vs INAB Comparison
Compare FND & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FND
- INAB
- Stock Information
- Founded
- FND 2000
- INAB 2016
- Country
- FND United States
- INAB United States
- Employees
- FND N/A
- INAB N/A
- Industry
- FND RETAIL: Building Materials
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- FND Consumer Discretionary
- INAB Health Care
- Exchange
- FND Nasdaq
- INAB Nasdaq
- Market Cap
- FND 7.9B
- INAB 14.5M
- IPO Year
- FND 2017
- INAB 2021
- Fundamental
- Price
- FND $83.78
- INAB $2.30
- Analyst Decision
- FND Hold
- INAB Strong Buy
- Analyst Count
- FND 18
- INAB 2
- Target Price
- FND $93.00
- INAB $108.00
- AVG Volume (30 Days)
- FND 1.8M
- INAB 170.0K
- Earning Date
- FND 07-31-2025
- INAB 08-07-2025
- Dividend Yield
- FND N/A
- INAB N/A
- EPS Growth
- FND N/A
- INAB N/A
- EPS
- FND 1.89
- INAB N/A
- Revenue
- FND $4,519,221,000.00
- INAB N/A
- Revenue This Year
- FND $7.05
- INAB N/A
- Revenue Next Year
- FND $10.65
- INAB N/A
- P/E Ratio
- FND $44.07
- INAB N/A
- Revenue Growth
- FND 2.96
- INAB N/A
- 52 Week Low
- FND $66.01
- INAB $2.05
- 52 Week High
- FND $124.68
- INAB $27.30
- Technical
- Relative Strength Index (RSI)
- FND 63.83
- INAB 39.46
- Support Level
- FND $79.71
- INAB $2.10
- Resistance Level
- FND $86.56
- INAB $2.30
- Average True Range (ATR)
- FND 2.67
- INAB 0.14
- MACD
- FND 0.78
- INAB 0.11
- Stochastic Oscillator
- FND 79.97
- INAB 49.56
About FND Floor & Decor Holdings Inc.
Floor & Decor Holdings Inc operates as a specialty retailer in the hard surface flooring market. Its stores offer a range of tile, wood, laminate, and natural stone flooring products, as well as decorative and installation accessories at everyday low prices. It appeals to a variety of customers including professional installers, commercial businesses, Do It Yourself (DIY) customers, and customers who buy the products for professional installation. Geographically, the group has a presence in the United States region and also offers its product through an e-commerce site.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.